-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 G9Gd2VYuVbuWrc2UQW0hdpwgWQ9SdZp/E6pxruPyRkuEP8gzuiErAXRXYkBKZft5
 d0vua1mNy0Ng8PSs0Wnvbg==

<SEC-DOCUMENT>0000950116-00-000739.txt : 20000403
<SEC-HEADER>0000950116-00-000739.hdr.sgml : 20000403
ACCESSION NUMBER:		0000950116-00-000739
CONFORMED SUBMISSION TYPE:	SC 13D
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20000331
GROUP MEMBERS:		ERIC RAINER BASHFORD CHARITABLE REMAINDER UNITRUST
GROUP MEMBERS:		HERRICK FEINSTEIN LLP /FA

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BOVIE MEDICAL CORP
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	INDUSTRIAL ORGANIC CHEMICALS [2860]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D
		SEC ACT:		
		SEC FILE NUMBER:	005-35626
		FILM NUMBER:		590090

	BUSINESS ADDRESS:	
		STREET 1:		734 WALT WHITMAN ROAD
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		5164215452

	MAIL ADDRESS:	
		STREET 1:		734 WALT WHITMAN ROAD
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERRICK FEINSTEIN LLP /FA
		CENTRAL INDEX KEY:			0001016570
		STANDARD INDUSTRIAL CLASSIFICATION:	 []
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D

	BUSINESS ADDRESS:	
		STREET 1:		2 PARK AVENUE 21ST FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		2125921491

	MAIL ADDRESS:	
		STREET 1:		2 PARK AVENUE
		CITY:			NEWYORK
		STATE:			NY
		ZIP:			10016
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D
<SEQUENCE>1
<TEXT>


<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                  Schedule 13D

                    Under the Securities Exchange Act of 1934
                               (Amendment No. 2__ )*



                            BOVIE MEDICAL CORPORATION
- --------------------------------------------------------------------------------
                                (Name of Issuer)

                                  Common Stock
- --------------------------------------------------------------------------------
                         (Title of Class of Securities)


                                   10211F 10 0
                           --------------------------
                                 (CUSIP Number)


Mr. Eric Rainer Bashford                       Irwin A. Kishner, Esq.
2689 Strang Boulevard                          Herrick, Feinstein LLP
Yorktown Heights, New York 10598               2 Park Avenue
Tel.: (914) 572-4327                           New York, New York 10016
                                               Tel.: (212) 592-1400


- --------------------------------------------------------------------------------
   (Name, Address and Telephone Number of Person Authorized to Receive Notices
                              and Communications)


                                 March 16, 2000
              ----------------------------------------------------
             (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].

*The remainder of this cover page shall be filed out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).

                        (Continued on following page(s))


                                Page 1 of 4 Pages

<PAGE>
_______________________________________________________________________________

CUSIP No.  10211F100               13D                     Page 2 of 4 Pages
_______________________________________________________________________________

    1      NAME OF REPORTING PERSON
           S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

           Eric Rainer Bashford Charitable Remainder Unitrust
______________________________________________________________________________

    2      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                                   (a)  [ ]
                                                                   (b)  [ ]
______________________________________________________________________________

    3      SEC USE ONLY
______________________________________________________________________________

    4      SOURCE OF FUNDS*

______________________________________________________________________________

    5      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
           PURSUANT TO ITEMS 2(d) OR 2(e)                            [ ]
______________________________________________________________________________

    6      CITIZENSHIP OR PLACE OF ORGANIZATION

_______________________________________________________________________________
               |     |
  NUMBER OF    |  7  |   SOLE VOTING POWER
   SHARES      |     |   904,000
BENEFICIALLY   |_____|________________________________________________________
  OWNED BY     |     |
   EACH        |  8  |   SHARED VOTING POWER
 REPORTING     |     |   -0-
  PERSON       |_____|________________________________________________________
   WITH        |     |
               |  9  |   SOLE DISPOSITIVE POWER
               |     |   904,000
               |_____|________________________________________________________
               |     |
               | 10  |   SHARED DISPOSITIVE POWER
               |     |   -0-
_______________|_____|_________________________________________________________

   11     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
          904,000
______________________________________________________________________________

   12     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
          CERTAIN SHARES*                                            [ ]
______________________________________________________________________________

   13     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
          6.13%
______________________________________________________________________________

   14     TYPE OF REPORTING PERSON*

______________________________________________________________________________

                     *SEE INSTRUCTIONS BEFORE FILLING OUT!
          INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
       (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION

<PAGE>



                             PART II TO SCHEDULE 13D

         This statement constitutes Amendment No. 2 to the statement on Schedule
13D filed with the Securities and Exchange Commission on February 19, 1998 (the
"Original Statement"). All defined terms hereunder have the meanings set forth
in the Original Statement. This Amendment No. 2 reflects certain material
changes in the information set forth in the Original Statement, as amended as of
March 10, 1999, as follows:

Item 1.  Security and Issuer

                  Shares of Common Stock

                  Bovie Medical Corporation
                  734 Walt Whitman Road
                  Suite 207
                  Melville, New York 11747
                  (hereinafter, the "Issuer")



Item 5.  Interest in Securities of the Issuer

                  (a)      Prior to March 16, 2000, the Trust was the beneficial
                           owner of 980,000 shares of Common Stock of the Issuer
                           (the "Trust Shares"), representing 6.65% of the
                           Issuer's Common Stock. The Trust has sold a total of
                           76,000 of the Trust Shares in a series of related
                           transactions described in item 5(c) below.

                  (c)      In a series of related transactions, concluding on
                           March 16, 2000, the Trust sold 76,000 shares of the
                           Issuer's Common Stock for cash at an average price
                           per share equal to $0.93. Such transactions were made
                           pursuant to Rule 144.

Item 6.  Contracts, Arrangements, Understandings of Relationships With Respect
         to Securities of the Issuer

         None.


Item 7.  Exhibits

         None


                                Page 3 of 4 Pages

<PAGE>



                                    SIGNATURE


         After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.






March 31, 2000                            By: /s/ Eric Rainer Bashford
- ----------------------                        --------------------------------
Date                                          Eric Rainer Bashford




                                Page 4 of 4 Pages




</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
